DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRASG12C-mutant cancer

• Published in: Journal of biomedical science Vol. 30; no. 1; pp. 1 - 18
• Main Authors: Chiou, Li-Wen, Chan, Chien-Hui, Jhuang, Yu-Ling, Yang, Ching-Yao, Jeng, Yung-Ming
• Format: Journal Article
• Language: English
• Published: Basel BioMed Central Ltd 29.06.2023; BioMed Central; BMC
• Subjects: Addictions; Analysis; Annexin V; Apoptosis; Bioassays; Cancer; Cancer therapies; Care and treatment; Caspase; Cell culture; Cell cycle; Cell growth; Cell viability; Clinical trials; Comet assay; Cyclin-dependent kinase inhibitor p21; Damage; Deoxyribonucleic acid; DNA; DNA biosynthesis; DNA damage; DNA replication; Drug addiction; Drug approval; Drug resistance; Drug withdrawal; Flow cytometry; Genetic aspects; Growth factors; Health aspects; Hyperactivity; Immunofluorescence; Iodides; Kinases; KRAS; Lung cancer; Lung cancer, Non-small cell; MAP kinase; Mitosis; Mitotic catastrophe; Mutants; Non-small cell lung carcinoma; Pancreatic cancer; Propidium iodide; Protein kinases; Proteins; Replication; Replication stress; Sarcoma; Scientific equipment and supplies industry; Small cell lung carcinoma; Sotorasib; Substance abuse; Tumor cell lines; Withdrawal; Xenotransplantation; United States; United States > US; Taiwan

Background Sotorasib is the first KRAS.sup.G12C inhibitor approved by the US Food and Drug Administration for treating KRAS.sup.G12C-mutant non-small-cell lung cancer (NSCLC). Clinical trials on the therapeutic use of sotorasib for cancer have reported promising results. However, KRAS.sup.G12C-mutan...